Massachusetts General Hospital, Harvard Medical School
Harvard University, USA
Dr. Kurtulus Gokduman received his B.Sc. degree in Biology, M.Sc. degree in Biotechnology, and Ph.D. degree in Biotechnology from Middle East Technical University, Ankara, Turkey. During his Ph.D. studies, he focused on the development of molecular genetic tools for Salmonella detection, as well as on the development of targeted and sustained delivery of Camptothecin anticancer drugs in bioactive form using iron oxide micro and nanoparticles. These researches have led to several publications and national/international patent applications. He performed post-doctoral research at Harvard Medical School, Harvard University, Boston, MA-USA, on the development of tumor on a chip test platform for bacterial cancer therapy, as well as on the investigation of hepatotoxicity profiles of super paramagnetic iron oxide nanoparticles using primary rat hepatocyte models. Currently his researches focus on cancer nanotechnology applications involving super paramagnetic iron oxide nanoparticles; bacterial cancer therapy; early diagnosis of cancer and other diseases using miRNA expression levels; treatment of cancer and other diseases using stem cells; and the development of tumor/organ on a chip models for medical diagnostics, targeted drug delivery, drug screening, and toxicological studies.
Cancer nanotechnology; bacterial cancer therapy; miRNAs;stem cell therapy; tumor/organ on a chip models